Immunome, Inc. (IMNM)
NASDAQ: IMNM · Real-Time Price · USD
20.76
+0.62 (3.08%)
At close: Jan 14, 2026, 4:00 PM EST
20.66
-0.10 (-0.48%)
After-hours: Jan 14, 2026, 7:58 PM EST
Immunome Market Cap
Immunome has a market cap or net worth of $2.29 billion as of January 14, 2026. Its market cap has increased by 248.17% in one year.
Market Cap
2.29B
Enterprise Value
2.02B
1-Year Change
248.17%
Ranking
Category
Stock Price
$20.76
Market Cap Chart
Since the IPO on October 2, 2020, Immunome's market cap has increased from $111.39M to $2.29B, an increase of 1,956.26%. That is a compound annual growth rate of 77.14%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jan 14, 2026 | 2.29B | -3.35% |
| Dec 31, 2025 | 2.37B | 257.53% |
| Dec 31, 2024 | 662.87M | 44.98% |
| Dec 29, 2023 | 457.21M | 1,605.70% |
| Dec 30, 2022 | 26.80M | -82.91% |
| Dec 31, 2021 | 156.82M | 53.68% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Oct 2, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Eli Lilly and Company | 961.00B |
| Johnson & Johnson | 526.55B |
| AbbVie | 392.16B |
| UnitedHealth Group | 303.42B |
| AstraZeneca | 299.25B |
| Novartis AG | 278.73B |
| Merck & Co. | 275.53B |
| Novo Nordisk | 262.20B |